Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.-Reference-Cited by-同舟云学术

Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.

Published:1981-12 Issue:6 Volume:12 Page:779-784
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:British Journal of Clinical Pharmacology

Author:

Bax ND,Lennard MS,Tucker GT

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1981.tb01306.x/fullpdf

Reference19 articles.

1. Effect of propranolol on morphine metabolism;BRUNK;Clin. Pharmac. Ther.,1974

2. Effect of metoprolol and propranolol on theophylline elimination;CONRAD;Clin. Pharmac. Ther.,1980

3. Studies on the different metabolic pathways of antipyrine in man. 1. Oral administration of 250, 500 and 1000 mg to healthy volunteers;DANHOF;Br. J. clin. Pharmac.,1979

4. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man;DANHOF;Pharmacolog.,1979

5. Studies on the different metabolic pathways of anti-pyrine in rats: Influence of phenobarbital and 3-methyl- cholanthrene treatment;DANHOF;Xenobiotica.,1979

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of an HPLC-UV method for the simultaneous determination of the antipsychotics clozapine, olanzapine and quetiapine, several beta-blockers and their metabolites;Biomedical Chromatography;2017-04-03

2. Phenazone (antipyrine);Meyler's Side Effects of Drugs;2016

3. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey;Journal of Neural Transmission;2015-05-05

4. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine;International Journal of Clinical Practice;2005-10-18

5. Influence of β-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol;British Journal of Clinical Pharmacology;2001-07